Highlights

• Haleos Labs shares gained nearly 5% and touched a fresh 52-week high.
• The stock has advanced more than 34% over the past one month.
• Trading activity remained limited with low market participation indicators.

Shares of HALEOS LABS LIMITED (NSE:HALEOSLABS) climbed 4.98% during Monday’s trading session and touched a new 52-week high of INR 1,739.10.

At 10:07 IST, the stock traded at INR 1,725.10 compared with the previous close of INR 1,643.30. The stock opened at INR 1,700 and moved between INR 1,660.50 and INR 1,739.10 during the session.

The company’s market capitalisation stood at approximately INR 522.03 crore, while free float market capitalisation was around INR 147.47 crore.

Source: TradingView

Monthly And Long-Term Gains Remain Elevated

Haleos Labs shares have witnessed sustained upward movement across multiple trading periods.

The stock has gained 14.24% over the past week and advanced 34.34% during the previous one month. On a year-to-date basis, shares have risen 32.02%. Over a three-year period, the stock has delivered returns exceeding 187%.

Source: NSE

Trading Volumes Stay Limited

Despite the sharp rise in share price, trading activity remained relatively low. Exchange data showed traded volume of approximately 0.01 lakh shares and traded value of around INR 0.23 crore.

The exchange also flagged that fewer than 100 unique PANs traded the stock during the previous 30 days. Additionally, close-to-close price movement exceeded 25% during the past one month. The stock’s annualised volatility stood at 59.80%.

Company Operates In Pharmaceutical Segment

HALEOS LABS LIMITED (NSE:HALEOSLABS)was incorporated in 2006 and operates in the pharmaceutical sector.

The company is engaged in manufacturing Active Pharmaceutical Ingredients (APIs) and related intermediates used in pharmaceutical production.

API manufacturers remain part of the broader pharmaceutical supply chain catering to formulation companies and healthcare product manufacturers.

Pharma Sector Continues To See Investor Interest

Pharmaceutical and healthcare-related stocks have remained under investor focus amid ongoing demand for domestic manufacturing capabilities and export opportunities.

Smaller-cap pharma companies have also witnessed increased price volatility in recent months due to lower liquidity and concentrated trading activity.

Haleos Labs’ recent movement comes amid broader interest in pharmaceutical manufacturing businesses listed on Indian exchanges.

Key Risks

• Trading volumes remain limited despite recent stock price gains.
• Low market participation may increase short-term volatility risks.
• SME and small-cap stocks may witness sharp price fluctuations.
• Pharmaceutical businesses remain exposed to regulatory compliance requirements.

Summary

Haleos Labs (NSE:HALEOSLABS) shares touched a fresh 52-week high after gaining nearly 5% during Monday’s session. The stock has delivered strong returns across one-month, year-to-date and long-term periods.

However, trading volumes remained limited and exchange indicators highlighted low participation levels. The company operates in the pharmaceutical sector with focus on manufacturing Active Pharmaceutical Ingredients and intermediates.

FAQs

Q: Why did Haleos Labs shares rise on May 11, 2026?
A: The stock gained amid continued momentum and touched a fresh 52-week high during trading.

Q: What business does Haleos Labs operate in?
A: The company manufactures Active Pharmaceutical Ingredients and pharmaceutical intermediates.

Q: Did Haleos Labs hit a new 52-week high?
A: Yes, the stock touched a fresh 52-week high of INR 1,739.10 on Monday.